Moreover, there is a significant association between the deregulation of CYTOR and many clinicopathological characteristics, such as tumor stage, lymph node metastases, infiltration, and adverse prognosis in patients with tumors.[84] CYTOR expression has found to be increased in various cancer forms, including gastric cancer, breast cancer, hepatocellular carcinoma, colon cancer, lung adenocarcinoma, esophageal squamous cell carcinoma, and RCC,[85–88] where CYTOR expression functions as an oncogenic lncRNA. Here, CYTOR is linked to breast carcinoma.